Mia Moore

Kent State University — United States

Medicine · Health Sciences

18h-index1.3kcitations101works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(22), COVID-19 epidemiological studies(19), HIV, Drug Use, Sexual Risk(18), SARS-CoV-2 and COVID-19 Research(14), HIV/AIDS drug development and treatment(10)

Publications101 total

Developmental and early-life stress-induced effects on 5-HT3R-expressing interneurons within auditory cortex
Neurobiology of Stress·2026· 1 citedOpen Access
Estimating Population Immunity and Impact of COVID-19 Vaccination in Washington State and Oregon
Open Forum Infectious Diseases·2025Open Access
Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis
Journal of the International AIDS Society·2025· 2 citedOpen Access
Review 2: "Excess HIV Infections and Costs Associated with Reducing Support for HIV Prevention Services in the United States: Projections Using Real-World Data"
2025Open Access
Reviews of "Excess HIV Infections and Costs Associated with Reducing Support for HIV Prevention Services in the United States: Projections Using Real-World Data"
2025Open Access
Dosing forgiveness of oral PrEP for cisgender women remains uncertain
Journal of the International AIDS Society·2025· 1 citedOpen Access
Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis
Vaccine·2025· 17 citedOpen Access
Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data
Epidemics·2024· 1 citedOpen Access
Review 1: "Understanding the Key Determinants of an HPV Therapeutic Vaccine: A Modeling Analysis"
2024Open Access
Reviews of "Understanding the Key Determinants of an HPV Therapeutic Vaccine: A Modeling Analysis"
2024Open Access
Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission
UNC Libraries·2023Open Access
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence
Nature Medicine·2023· 19 citedOpen Access
When does humoral memory enhance infection?
PLoS Computational Biology·2023· 2 citedOpen Access
Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis
Journal of the International AIDS Society·2023· 26 citedOpen Access
Estimating efficacy of tenofovir disoproxil fumarate and emtricitabine for HIV prevention in cisgender women with partial adherence.
Research Square (Research Square)·2023Open Access
Type II Endoleaks and Culprit Vessels: Will 4D MRI Change the Paradigm?
European Journal of Vascular and Endovascular Surgery·2023· 1 cited
Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083
The Lancet Regional Health - Americas·2023· 19 citedOpen Access
Estimating benefits of using on-demand oral prep by MSM: a comparative modeling study of the US and Thailand
EClinicalMedicine·2022· 11 citedOpen Access
The role of perceived patient injustice on pain related and functional outcomes in orthopaedic patients; a systematic review
Journal of Orthopaedics·2022· 1 citedOpen Access
Anterior Insula–Associated Social Novelty Recognition: Pivotal Roles of a Local Retinoic Acid Cascade and Oxytocin Signaling
American Journal of Psychiatry·2022· 17 cited
page 1 of 6Next →

Frequent Co-authors

Dobromir Dimitrov(20), Deborah Donnell(10), Joshua T. Schiffer(10), Marie‐Claude Boily(10), David A. Swan(9), Chloe Bracis(9), Daniel B. Reeves(9), Kate M. Mitchell(8), Eileen Burns(6), Myron S. Cohen(6), Hasan Ahmed(6), Rustom Antia(6), Young S. Lo(5), Holly Janes(4), Laura Matrajt(4), Sarah E. Stansfield(4), Rama Akondy(4), Rafi Ahmed(4), James P. Hughes(4), Michael E. Pierce(3)